TL;DR: ASM.D. Aesthetics now offers DAXXIFY®, JUVÉDERM®, XEOMIN®, BOTOX®, and Dysport®. These aren't five versions of the same shot. They differ at the molecular level in ways that affect how fast they work, how long they last, and how your body responds to them over years of treatment. Understanding those differences (not just brand names) is what actually helps you pick the right one.
- Why "Botox" Isn't a Generic Word for Everything
- The Hidden Ingredient That Separates These Products
- Neuromodulators vs. Fillers: Different Problems, Different Tools
- Side-by-Side Comparison
- How to Actually Choose
- References
Why "Botox" Isn't a Generic Word for Everything
Most people use "Botox" the way they use "Kleenex." It's become shorthand for any wrinkle-relaxing injectable, even when the product in the syringe is XEOMIN, Dysport, or DAXXIFY. That habit isn't just semantics. It can lead patients to assume all neuromodulators behave identically, which means they never ask the one question that actually matters for their results: which formula fits my face, my schedule, and my long-term goals?
Here's the part almost nobody explains at a consultation: every one of these products is built from the same core molecule, botulinum toxin type A, but the manufacturing process wraps that molecule in different accessory ingredients. Those differences change onset time, how far the product spreads from the injection site, how long results last, and even how your immune system reacts to repeated treatments over the years.
The Hidden Ingredient That Separates These Products
Traditional BOTOX and Dysport are formulated with accessory proteins attached to the active toxin. These proteins helped early manufacturing processes stabilize the product, but they're biologically unnecessary for the toxin's wrinkle-smoothing effect. Over years of repeated injections, some patients develop antibodies against these accessory proteins, which can eventually reduce how well the treatment works, a phenomenon documented in clinical literature on secondary non-response (Kerscher et al., 2021).
XEOMIN was designed specifically to address this. It's a "naked" formulation, meaning the accessory proteins are stripped out during purification, leaving just the active neurotoxin. Fewer proteins means fewer antigens for your immune system to react to, which is part of why some providers recommend it for patients who get treated frequently and want to protect their long-term response.
DAXXIFY takes a different approach entirely. Instead of human serum albumin or animal-derived stabilizers used in older formulations, it uses a peptide-based stabilizing technology. This is a newer manufacturing method, and it's part of why DAXXIFY has shown a longer average duration in clinical trials, roughly 6 to 9 months for some patients compared to the typical 3 to 4 months seen with BOTOX and Dysport (Nestor et al., 2022, SAKURA trial data).
Dysport, meanwhile, has smaller molecule clusters than BOTOX, which allows it to diffuse slightly more through tissue. That's not a flaw, it's actually an advantage for treating broader areas like the forehead where even coverage matters more than pinpoint precision (Rzany et al., 2013).
Neuromodulators vs. Fillers: Different Problems, Different Tools
Here's a mix-up we see constantly: patients booking a consultation for "wrinkle filler" when what they actually need is a neuromodulator, or vice versa. These are not interchangeable categories.
BOTOX, XEOMIN, Dysport, and DAXXIFY are neuromodulators. They work by temporarily blocking nerve signals to specific muscles, which softens the repetitive muscle movement that creates dynamic wrinkles, think crow's feet from squinting or forehead lines from raised eyebrows. They don't add volume anywhere.
JUVÉDERM is a hyaluronic acid filler. It works completely differently, by physically restoring lost volume or adding structure, whether that's filling in cheeks that have thinned with age, softening nasolabial folds, or enhancing lip shape. Hyaluronic acid is a sugar molecule your body already produces naturally, and it binds water to plump tissue from within (Fakhari & Berkland, 2013).
Some patients benefit from both in the same visit: a neuromodulator to calm the muscle movement causing a line, and filler to restore volume that's been lost to it. That combination approach is common and often more effective than either treatment alone.
Side-by-Side Comparison
| Product | Category | Typical Onset | Typical Duration | Notable Feature |
|---|---|---|---|---|
| BOTOX® | Neuromodulator | 3–7 days | 3–4 months | Most studied, longest FDA track record |
| Dysport® | Neuromodulator | 2–5 days | 3–4 months | Smaller molecule, spreads more evenly over larger areas |
| XEOMIN® | Neuromodulator | 4–7 days | 3–4 months | No accessory proteins, may lower antibody risk over time |
| DAXXIFY® | Neuromodulator | 2–4 days | 6–9 months | Peptide-based formulation, longest duration on the market |
| JUVÉDERM® | Hyaluronic acid filler | Immediate | 6–18 months (varies by formula) | Restores volume rather than relaxing muscle |
How to Actually Choose
The right choice depends on things a brand name can't tell you. How expressive is your face at rest? How often are you realistically going to come in for touch-ups? Are you trying to soften movement lines or replace lost volume? Do you sweat heavily or spend a lot of time in intense sun and heat, which can affect how quickly your body metabolizes certain treatments?
A patient who wants to minimize appointments might lean toward DAXXIFY for its longer duration. Someone getting treated every few months for years might prioritize XEOMIN's lower antibody profile. A patient dealing with volume loss in the cheeks needs JUVÉDERM, not a neuromodulator at all. None of this is one-size-fits-all, and that's exactly why we expanded our offerings instead of sticking to a single product line.
A consultation isn't just a formality here. It's where we actually map your facial anatomy, movement patterns, and goals to the product that fits, rather than defaulting to whatever's most familiar.
References
- Kerscher M, Wanitphakdeedecha R, Trindade de Almeida A, et al. Impact of Sustained Immunogenicity on Efficacy and Safety of Botulinum Toxin Type A. J Cosmet Dermatol. 2021.
- Nestor MS, Fabi SG, Beleznay K, et al. Efficacy and Safety of DaxibotulinumtoxinA for Injection (SAKURA Trials). Dermatol Surg. 2022.
- Rzany B, Ascher B, Fratila A, et al. Efficacy and Safety of AbobotulinumtoxinA (Dysport) for the Treatment of Glabellar Lines. Aesthet Surg J. 2013.
- Fakhari A, Berkland C. Applications and Emerging Trends of Hyaluronic Acid in Tissue Engineering, as a Dermal Filler and in Osteoarthritis Treatment. Acta Biomater. 2013.
- U.S. Food and Drug Administration. BOTOX Cosmetic, XEOMIN, DAXXIFY, Dysport Prescribing Information. www.fda.gov